Businessweek Archives

Sir Richard B. Sykes


Cover Story -- The Best Managers: Top Managers of 1996

SIR RICHARD B. SYKES

As patents for its Glaxo Holdings' blockbuster antiulcer drug, Zantac, began to expire in 1995, the prognosis looked grim. But with bold strokes such as the $14 billion acquisition of Wellcome, CEO SIR RICHARD B. SYKES has kept the British drug giant healthy. Even as Zantac sales slid, Glaxo's 1996 revenues grew some 5%, to $13.9 billion. 1997 could be rough, but upcoming AIDS and flu treatments should be big hits down the road.Return to top

Return to top


Cash Is for Losers
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus